| Literature DB >> 25147812 |
Susana Machado1, Sofia Calado2, Diogo Bitoque3, Ana Vanessa Oliveira2, Christer L Øpstad4, Muhammad Zeeshan5, Hans-Richard Sliwka4, Vassilia Partali4, Michael D Pungente5, Gabriela A Silva6.
Abstract
Recent success in the treatment of congenital blindness demonstrates the potential of ocular gene therapy as a therapeutic approach. The eye is a good target due to its small size, minimal diffusion of therapeutic agent to the systemic circulation, and low immune and inflammatory responses. Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to impn>rove nucleic acid delivery. Our objective is to evaluate the efficiency of novel cationic retinoic and carotenoicEntities:
Mesh:
Substances:
Year: 2014 PMID: 25147812 PMCID: PMC4131563 DOI: 10.1155/2014/703253
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1C20-18, C20-20, and C30-20 cationic amphiphilic glycol polyene phospholipids. The color of the polyene chain indicates approximately the visually appearance of the compounds. Glycol backbone green, hydrophilic part blue.
Figure 2Reference compounds. DC-Chol and cationic glycerophosphospholipid EPC with two C14:0 chains. Glycerol backbone green, hydrophilic parts blue.
Figure 3Colipids. Neutral cholesterol (Chol) and zwitterionic glycerophosphospholipid DOPE with two C18:1 chains. Glycerol backbone green, hydrophilic parts blue.
Size and surface charge (as measured by zeta potential, ZP) of C20-18, C20-20, C30-20, DC-Chol, and EPC lipoplexes in PBS at varying N/P molar charge ratios with either Chol or DOPE as colipids.
| Lipid | Colipid |
|
| Mode (nm) | Pdl | ZP (mV) |
|---|---|---|---|---|---|---|
|
|
| 1180 | 477 | 0.718 | −55 ± 5.61 | |
|
|
| 1480 | 455 | 0.840† | −55 ± 5.19 | |
|
| 1220 | 516 | 0.611 | −65 ± 3.11 | ||
|
| 900 | 441 | 0.664 | −63 ± 0.65 | ||
|
|
| 1310 | 600 | 0.424 | −69 ± 2.76 | |
|
| 1290 | 506 | 0.768∗ | −65 ± 1.06 | ||
|
| ||||||
|
|
| 510† | 488 | 0.220† | −54 ± 1.65 | |
|
|
| 360 | 380 | 0.058 | −57 ± 1.01 | |
|
| 320† | 322† | 0.234† | −57 ± 0.85 | ||
|
| 1410 | 528 | 0.750 | −57 ± 1.22 | ||
|
|
| 930 | 625 | 0.366 | −58 ± 1.96 | |
|
| 2010∗ | 656 | 0.862 | −54 ± 1.98 | ||
|
| ||||||
|
|
| 320 | 256 | 0.322 | −41 ± 10.81 | |
|
|
| 390 | 361 | 0.285 | −51 ± 4.57 | |
|
| 1523∗ | 490 | 0.702∗ | −43 ± 8.11 | ||
|
| 550 | 487 | 0.425 | −53 ± 6.73 | ||
|
|
| 910 | 406 | 0.624 | −38 ± 7.77 | |
|
| 1270 | 453 | 0.596 | −36 ± 1.74 | ||
|
| ||||||
|
|
| 560 | 548 | 0.130 | −53 ± 0.27 | |
|
|
| 570 | 537 | 0.157 | −59 ± 1.03 | |
|
| 660 | 537 | 0.257 | −61 ± 0.37 | ||
|
| 640 | 465 | 0.304 | −53 ± 1.43 | ||
|
|
| 970 | 500 | 0.155 | −41 ± 0.88 | |
|
| 750 | 594 | 0.147 | −62 ± 0.50 | ||
|
| ||||||
|
|
| 500† | 355∗† | 0.353 | −36 ± 1.43* | |
|
|
| 820 | 763 | 0.178 | −60 ± 1.86† | |
|
| 710 | 697 | 0.260 | −66 ± 0.58† | ||
|
| 1500 | 937∗ | 0.144 | −30 ± 1.71 | ||
|
|
| 970 | 605 | 0.419 | −40 ± 1.43 | |
|
| 1140 | 768 | 0.220 | −40 ± 0.12 | ||
†Comparison between Chol and DOPE formulations of one lipid with the same molar charge ratio; *Comparison between ratios (0.5 : 1 versus 1 : 1 or 1 : 1 versus 1.5 : 1) of the same lipid formulation.
Figure 4Gel retardation assays with lipoplexes C20-18 (a), C20-20 and C30-20 (b), DC-Chol (c), and EPC (d) with DOPE and Chol as colipids. Molar charge ratios N/P used were 0.5 : 1, 1 : 1, and 1.5 : 1. Retention of DNA increases with increasing molar charge ratios.
Figure 5DC-Chol lipoplex cytotoxicity. ARPE-19 cell viability for DC-Chol lipoplexes with either Chol or DOPE as colipid at various N/P ratios incubated up to 72 h. Horizontal line at 75% viability represent the threshold according to the ISO standard for in vitro testing of biological devices. C+ represents untreated cells and C− represents cells treated to induce cell death. Statistical significance (∗) of 95% (P < 0.05).
Figure 6EPC lipoplex cytotoxicity. ARPE-19 cell viability for EPC lipoplexes with either Chol or DOPE as colipids at various N/P molar charge ratios incubated up to 72 h. Horizontal line at 75% viability represents the threshold according to the ISO standard for in vitro testing of biological devices. C+ represents untreated cells and C− represents cells treated to induce cell death. Statistical significance (∗) of 95% (P < 0.05).
Figure 7C20-18 lipoplex cytotoxicity. ARPE-19 cell viability for C20-18 lipoplexes with either Chol or DOPE as colipid at various N/P ratios incubated up to 72 h. Horizontal line at 75% viability represents the threshold according to the ISO standard for in vitro testing of biological devices. C+ represents untreated cells and C− represents cells treated to induce cell death. Statistical significance (∗) of 95% (P < 0.05).
Figure 8C20-20 lipoplex cytotoxicity. ARPE-19 cell viability for C20-20 lipoplexes with either Chol or DOPE as colipid at various N/P ratios incubated up to 72 h. Horizontal line at 75% viability represents the threshold according to the ISO standard for in vitro testing of biological devices. C+ represents untreated cells and C− represents cells treated to induce cell death. Statistical significance (∗) of 95% (P < 0.05).
Figure 9C30-20 lipoplex cytotoxicity. ARPE-19 cell viability for C30-20 lipoplexes with either Chol or DOPE as colipid at various N/P ratios incubated up to 72 h. Horizontal line at 75% viability represents the threshold according to the ISO standard for in vitro testing of biological devices. C+ represents untreated cells and C− represents cells treated to induce cell death. Statistical significance (∗) of 95% (P < 0.05).
Figure 10Immunohistochemistry detection of Iba1 in mouse retinas injected with C20-20/DOPE lipoplexes at the N/P molar charge ratio 0.5 : 1. Magnification: 100x and scale bar: 50 μm.
Figure 11Hematoxylin and eosin staining of mouse retinas injected with C20-20/DOPE lipoplexes at the N/P molar charge ratio 0.5 : 1, showing the maintenance of the integrity of the retinal layered structure. Magnification: 100x and scale bar: 50 μm.
Figure 12Qualitative assessment of lipoplex transfection. ARPE-19 cells were incubated with lipoplexes containing lipids C20-18, C20-20, or C30-20 against reference lipids DC-Chol and EPC with either Chol or DOPE as colipid at N/P molar ratio 0.5 : 1 for 4 h and GFP-expressing cells evaluated by fluorescence microscopy after 72 h. Magnification: 100x and scale bar: 100 μm.
Figure 13The transfection efficiency of lipoplexes. ARPE-19 cells were incubated with lipoplexes containing lipids C20-18, C20-20, or C30-20 against reference lipids DC-Chol and EPC with either Chol or DOPE as colipid at N/P molar ratio 0.5 : 1 for 4 h and transfection efficiencies, measured by GFP expression, determined by flow cytometry after 72 h. Statistical significance (∗) of 95% (P < 0.05).